Feb 17, 2026 10:48AM
Feb 12, 2026 07:30AM
Jan 12, 2026 07:01AM
Jan 12, 2026 07:00AM
Dec 22, 2025 07:06AM
Dec 21, 2025 04:00AM
Nov 3, 2025 07:00AM Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Oct 8, 2025 07:01AM
Oct 8, 2025 07:00AM
Sep 10, 2025 07:00AM
Sep 10, 2025 07:00AM
Aug 11, 2025 07:30AM
May 14, 2025 09:31AM
May 12, 2025 04:05PM Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hem
Apr 12, 2025 04:00AM
Feb 24, 2025 08:41AM
Feb 24, 2025 08:40AM
Feb 19, 2025 07:30AM
Jan 13, 2025 08:30AM
Jan 2, 2025 07:02AM
Jan 2, 2025 07:00AM Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer
Dec 9, 2024 08:00AM
Dec 3, 2024 07:00AM
Nov 18, 2024 07:00AM
Nov 6, 2024 07:57AM
Nov 5, 2024 07:30AM
Oct 31, 2024 07:31AM
Oct 31, 2024 07:30AM Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Aug 6, 2024 07:30AM
Jun 1, 2024 01:45PM
May 8, 2024 07:30AM
May 8, 2024 07:30AM
May 8, 2024 07:30AM
Apr 24, 2024 04:01PM
Mar 13, 2024 04:35PM Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)
Feb 29, 2024 07:30AM
Jan 8, 2024 08:36AM
Jan 8, 2024 08:30AM
Dec 10, 2023 08:15PM
Nov 6, 2023 07:00AM
Nov 2, 2023 09:20AM
Nov 2, 2023 07:30AM Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Oct 30, 2023 08:02AM
Oct 30, 2023 08:00AM
Sep 26, 2023 07:00AM
Sep 1, 2023 08:01AM
Sep 1, 2023 08:00AM
Aug 2, 2023 07:30AM
Jul 25, 2023 03:00PM Karyopharm Therapeutics (KPTI) Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Jul 25, 2023 03:00PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All